Systematic evaluation of paediatric cohort with iron refractory iron deficiency anaemia (IRIDA) phenotype reveals

Prateek Bhatia1, Aditya Singh1, Avani Hegde1

  • 1Paediatric Haematology-Oncology Unit, Department of Paediatrics, Advanced Paediatric Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, India.

Insights

Iron refractory iron deficiency anemia (IRIDA) was identified in Indian children with unexplained anemia. Genetic analysis of TMPRSS6 mutations revealed potential causes, but other refractory causes should be considered.

Area of Science:

  • Pediatric Hematology
  • Genetics
  • Nutritional Anemias

Background:

  • Iron deficiency anemia (IDA) is common in children, but some cases are refractory to oral iron therapy.
  • Identifying the underlying causes of refractory anemia is crucial for effective treatment.

Purpose of the Study:

  • To investigate the prevalence and genetic basis of iron refractory iron deficiency anemia (IRIDA) in Indian children.
  • To evaluate the role of TMPRSS6 gene mutations in children with unexplained refractory anemia.

Main Methods:

  • Systematic screening of 550 children with unexplained moderate to severe microcytic anemia.
  • Oral iron challenge test for 4 weeks in eligible cases.
  • Biochemical evaluation (plasma iron, ferritin, hepcidin) and TMPRSS6 gene sequencing in refractory cases.

Main Results:

  • 11% of screened children (60/550) showed refractoriness to oral iron.
  • IRIDA phenotype was observed in 38.3% (23/60) of refractory cases.
  • Potentially deleterious TMPRSS6 gene variations were identified in 60% (12/20) of evaluated IRIDA cases.

Conclusions:

  • A significant proportion of children with refractory anemia in India may have IRIDA.
  • TMPRSS6 gene mutations are a relevant genetic cause of IRIDA in this population.
  • A comprehensive diagnostic approach is recommended, considering other causes of iron refractoriness before extensive genetic testing.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
60
Translation01:31

Translation

Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Proteins are...
21.1K
Translation01:31

Translation

Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...
158.7K
iPS Cell Differentiation01:22

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
3.2K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
76
Pedigree Analysis01:35

Pedigree Analysis

Overview
90.3K